Cite
HARVARD Citation
Mir, O. et al. (n.d.). Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet oncology. 17 (5), pp. 632-641. [Online].